Treatment of primary aldosteronism

M Quinkler, Paul Stewart

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The prevalence of primary hyperaldosteronism approaches 10% of all hypertensive patients, and besides efficient diagnostic procedures, effective treatment is of increasing importance to reverse increased morbidity and mortality. Aldosterone-producing adenoma and unilateral adrenal hyperplasia are amenable to cure by endoscopic adrenalectomy. Bilateral adrenal hyperplasia (micro- or macronodular), which comprises two-thirds of primary hyperaldosteronism, is treated primarily by mineralocorticoid receptor antagonists (starting dose 12.5-25 mg/day spironolactone with titration up to 100 mg/day, alternatively 50-100 mg/day eplerenone). If blood pressure is not normalised by this first-line treatment, additional treatment with potassium-sparing diuretics (amiloride or triamterene) or calcium channel antagonists is necessary. The start of medication should be closely monitored by serum electrolyte and creatinine controls. (C) 2010 Elsevier Ltd. All rights reserved.
Original languageEnglish
Pages (from-to)923-932
Number of pages10
JournalBest practice & research. Clinical endocrinology & metabolism
Volume24
Issue number6
DOIs
Publication statusPublished - 1 Dec 2010

Keywords

  • mineralocorticoid receptor
  • adrenalectomy
  • conn's adenoma
  • spironolactone
  • primary aldosteronism
  • eplerenone

Fingerprint

Dive into the research topics of 'Treatment of primary aldosteronism'. Together they form a unique fingerprint.

Cite this